← All diseases
Blood and bone marrow
Myelodysplastic syndrome
Would you like to receive a message when there is new research about Myelodysplastic syndrome? This is possible with an account. Create a free account or log in.
Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence
Read in plain language what each study is about? With Premium, one sentence appears above every publication explaining what was investigated — and you receive a message as soon as there is new research on Myelodysplastic syndrome. View what Premium costs.
Publications and studies (1773)
- Recent trends in hospitalizations for myelodysplastic syndromes and polycythemia vera in England and Wales. (2026/07/24) ♡
- Severe Folate Deficiency Mimicking Myelodysplastic Syndrome/Acute Myeloid Leukemia: A Case Report. (2026/07/24) ♡
- Data-augmented machine learning refines the effective-concentration estimate for eculizumab in complement-mediated diseases. (2026/07/24) ♡
- Systematic reviewiAll research on one question is searched according to fixed rules and compared side by side, so that no studies with poor outcomes are missed. Occult squamous cell carcinoma presenting as oligometastatic lymphadenopathy. A systematic review with a case report. (2026/07/24) ♡
- Prognostic Validation of IPSS-M Versus ELN 2022/2024 in MDS/AML Patients: A Survival and Treatment Response Analysis. (2026/07/22) ♡
- Disease Burden, Inadequate Hematocrit Control, and Thromboembolic Events in Patients with Polycythemia Vera Despite Current Standard of Care Treatment: A Retrospective Claims Study. (2026/07/22) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Hypomethylating agents are the current therapy backbone for MDS and AML relapsing after allogeneic hematopoietic stem cell transplantation. (2026/07/22) ♡
- The Nicotinamide Salvage Pathway is a Metabolic Vulnerability of High-Risk MDS Stem Cells. (2026/07/21) ♡
- Clinical association between myelodysplastic syndrome and de novo bone metastasis in urothelial carcinoma. (2026/07/21) ♡
- Acute Myeloid Leukemia Subtype-Specific Prognostic Value of NGS in the Setting of Intensive Chemotherapy. (2026/07/18) ♡
- LncRNA KIAA0125 promotes the proliferation of Kasumi-1 cells through the miR-4640-5p/KCNQ1 axis with associated changes in the Wnt/β-catenin signaling pathway. (2026/07/17) ♡
- Pulmonary alveolar proteinosis diagnosed during leuprorelin acetate therapy for ovarian endometrioma: a case report. (2026/07/17) ♡
- RNA and Mitochondrial Reprogramming Associated with Azacytidine Treatment in Higher-Risk Myelodysplastic Syndromes: A Pilot Study. (2026/07/17) ♡
- Comprehensive analysis of prognostic factors in myelodysplastic syndromes with isolated deletion of chromosome 5q. (2026/07/16) ♡
- Non-invasive differentiation between aplastic anemia and myelodysplastic syndromes based on an 8-feature lightGBM model: A multicenter external validation study. (2026/07/16) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. A case of true acute eosinophilic leukemia arising from myelodysplastic syndrome. (2026/07/15) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. GATA2 deficiency: enhancer deregulation, immune surveillance failure, and clonal evolution. (2026/07/15) ♡
- Venetoclax-enhanced reduced-intensity conditioning in older patients aged ≥55 years with high-risk myeloid malignancies undergoing allogeneic peripheral blood stem cell transplantation: A phase II study. (2026/07/15) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. Reply to 'Immortal time bias limits the conclusion that post-transplant hypomethylating agent maintenance improves outcomes in myelodysplastic syndromes'. (2026/07/15) ♡
- Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. Excess risk for cardiovascular and noncardiovascular comorbidities and multimorbidity among patients with myelodysplastic syndrome: A systematic review and meta-analysis. (2026/07/15) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Reactive versus clonal monocytosis: chronic myelomonocytic leukaemia. (2026/07/15) ♡
- Pulmonary Nocardiosis Diagnosed by Plasma Metagenomic Next-Generation Sequencing in a Patient With Recurrent Febrile Neutropenia. (2026/07/15) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. Acquired Erythropoietic Protoporphyria Associated With Myelodysplastic Syndrome: A "Two-Hit" Mechanism Involving 18q21 Abnormality. (2026/07/14) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Activin Signaling Inhibitors in Pulmonary Hypertension: A State-of-the-Art Review. (2026/07/14) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Therapy-related myelodysplastic syndrome rapidly evolving to acute myeloid leukemia following CAR-T cell therapy in a patient with refractory diffuse large B-cell lymphoma: a case report. (2026/07/14) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Venetoclax combined with azacitidine in the treatment of secondary myelodysplastic syndrome following multiple myeloma: a case report and literature review. (2026/07/14) ♡
- Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study. (2026/07/13) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Peptide-Drug Conjugates for Targeted Delivery in Hematological Malignancies: From Design Principles to Clinical Application. (2026/07/13) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. VEXAS Mimicking Antiphospholipid Syndrome: Diagnostic Challenges of False-Positive Antiphospholipid Antibodies. (2026/07/11) ♡
- Weakened macrophage antibacterial capacity in myelodysplastic syndrome. (2026/07/10) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Case Report: Durable response to mirvetuximab soravtansine in a patient with platinum-sensitive ovarian cancer and a diagnosis of myelodysplastic syndrome. (2026/07/09) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Case Report: Growth hormone deficiency and response to treatment in MIRAGE syndrome: expanding the endocrine phenotype. (2026/07/07) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Real-World Management of HMA-Related Myelosuppression During MDS Treatment in the Canadian Landscape. (2026/07/07) ♡
- Evaluating response criteria in myelodysplastic/myeloproliferative neoplasms: a systematic review and meta-analysis. (2026/07/03) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Repeated courses of sequential venetoclax and donor lymphocyte infusions in a patient with relapsed high-risk myelodysplasia following allogeneic stem cell transplantation: a case report. (2026/07/02) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Artificial Intelligence in Hematology. (2026/07/01) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. Letter To the Editor: "Outcome of Low-Dose Azacitidine in Patients of Lower-Risk Myelodysplastic Syndromes". (2026/07/01) ♡
- Outcome of Low Dose Azacitidine in Patients of Lower Risk Myelodysplastic Syndromes. (2026/07/01) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. Outcome of Low Dose Azacitidine in Patients of Lower Risk Myelodysplastic Syndromes. (2026/07/01) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Factors implicated in underutilization and poor persistence with hypomethylating agent therapy in myelodysplastic syndromes and chronic myelomonocytic leukaemia in Pakistan. (2026/07/01) ♡
- Clinical and Prognostic Significance of CEBPA Mutations in Myelodysplastic Syndromes. (2026/07/01) ♡
- Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. Real-World Luspatercept Evidence in Myelodysplastic Neoplasms: A Systematic Review and Bayesian Meta-Analysis. (2026/07/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. The role and therapeutic potential of nanotechnology-mediated ferroptosis regulation in myelodysplastic syndromes. (2026/07/01) ♡
- Mismatched Unrelated vs Matched Related Donor Transplant With Posttransplant Cyclophosphamide Among Patients With Blood Cancers. (2026/07/01) ♡
- TP53 Amplification, a Rare but Recurrent Alteration in Myeloid Neoplasms. (2026/07/01) ♡
- "An opportunity to spend time with each other": The importance of mealtimes for carepartners of older adults with acute myeloid leukemia and myelodysplastic syndromes. (2026/07/01) ♡
- Azacitidine Is Well-Tolerated and Is Associated with High Response Rate in Elderly Patients with Higher-Risk Myelodysplastic Syndromes: A Single Center Observational Study. (2026/06/30) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Newly Diagnosed VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome in a Patient Presenting With Legionella Pneumonia. (2026/06/30) ♡
- Gastrointestinal adverse reactions and metabolism-nutrition disorders associated with hypomethylating agents: a pharmacovigilance study with exploratory mechanistic analysis. (2026/06/30) ♡
- Colony-Forming Unit Assay Adapted For Patient-Derived Bone Marrow and Peripheral Blood Mononuclear Cells. (2026/06/26) ♡
codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.